A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2002
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172959 Compositions and methods relating to lung specific genes and proteins
11/21/2002	US20020172958 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
11/21/2002	US20020172722 For therapy and in cosmetics
11/21/2002	US20020172705 Bioengineered tissue constructs and methods for producing and using thereof
11/21/2002	US20020172682 Using heat shock proteins to increase immune response
11/21/2002	US20020172678 For regulating cellular proliferation and chemotaxis
11/21/2002	US20020172674 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth
11/21/2002	CA2460603A1 Unigene unidirectional antisense library
11/21/2002	CA2449292A1 Dipeptide derivatives
11/21/2002	CA2449188A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447574A1 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
11/21/2002	CA2447518A1 Therapeutic use of rank antagonists
11/21/2002	CA2447513A1 Compositions and methods for treating tumors bearing hmfg and cea antigens
11/21/2002	CA2447408A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	CA2447314A1 Arginine derivatives
11/21/2002	CA2447305A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002	CA2447286A1 Random gene unidirectional antisense library
11/21/2002	CA2447275A1 Therapeutic delivery of carbon monoxide
11/21/2002	CA2447184A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	CA2447116A1 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	CA2447084A1 Benzamidoacetonitriles and their use as antiparasitics
11/21/2002	CA2447052A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	CA2447050A1 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002	CA2446945A1 Method of preventing cell death using segments of neural thread proteins
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2446839A1 Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
11/21/2002	CA2446797A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	CA2446747A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446736A1 Chemoprotection using amifostine and related compounds
11/21/2002	CA2446717A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	CA2446641A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	CA2446593A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2446582A1 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	CA2446180A1 Cytokine polypeptides
11/21/2002	CA2446072A1 Treating epidermolysis bullosa with thymosin beta 4
11/21/2002	CA2445922A1 Estrogen receptor modulators
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2445003A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	CA2443721A1 Sulfonamide derivatives
11/21/2002	CA2443191A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	CA2442635A1 Gastrokines and derived peptides including inhibitors
11/21/2002	CA2429718A1 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
11/20/2002	WO2001091755A1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
11/20/2002	WO2001090252A1 Gelling composition
11/20/2002	EP1258529A2 FLIP Gene and FLIP Protein
11/20/2002	EP1258491A1 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
11/20/2002	EP1258490A1 Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates
11/20/2002	EP1258484A1 Novel isoxazole and thiazole compounds and use thereof as drugs
11/20/2002	EP1258474A2 Alkylamide compounds
11/20/2002	EP1258253A1 Novel remedies with the use of beta3 agonist
11/20/2002	EP1258247A1 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
11/20/2002	EP1258245A2 Accelerated release composition containing bromocriptine
11/20/2002	EP1257657A2 Autoregulatory expression vector for gene therapy
11/20/2002	EP1257648A1 Antagonistic selective binding agents of osteoprotegerin binding protein
11/20/2002	EP1257646A2 Transporters and ion channels
11/20/2002	EP1257578A2 Transporters and ion channels
11/20/2002	EP1257573A2 New transcription factor carp-2
11/20/2002	EP1257560A1 Bcl-2-like polynucleotides, polypeptides, and antibodies
11/20/2002	EP1257556A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
11/20/2002	EP1257555A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
11/20/2002	EP1257554A1 Benzoxathiepino[3,4-b]pyridine derivatives, process for their preparation and their use as medicaments
11/20/2002	EP1257553A1 Pyrrolopyrimidinone derivatives, process of preparation and use
11/20/2002	EP1257550A1 Platelet adp receptor inhibitors
11/20/2002	EP1257548A1 Benzofuran carboxamides and their therapeutic use
11/20/2002	EP1257547A1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
11/20/2002	EP1257546A1 Kinase inhibitors
11/20/2002	EP1257543A1 Pyridinylimidazoles
11/20/2002	EP1257541A2 Polypharmacophoric agents
11/20/2002	EP1257537A1 Therapeutic morpholino-substituted compounds
11/20/2002	EP1257536A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/20/2002	EP1257530A1 Aminosulfonylbiphenyl derivatives
11/20/2002	EP1257528A1 Aminoalcohol derivatives
11/20/2002	EP1257526A1 Aniline-derived ligands for the thyroid receptor
11/20/2002	EP1257299A2 Radioactive therapeutic liposomes
11/20/2002	EP1257296A2 Caspase activated prodrugs therapy
11/20/2002	EP1257292A1 Use of il-18 inhibitors
11/20/2002	EP1257289A1 Immunotherapy using interleukin 13 receptor subunit alpha 2
11/20/2002	EP1257282A1 Pancreatic stem cells and their use in transplantation
11/20/2002	EP1257276A1 Antiviral azaindole derivatives
11/20/2002	EP1257264A1 Estrogen receptor modulators
11/20/2002	EP1257263A2 Microcompetiton and human disease
11/20/2002	EP1257253A2 Cosmetic preparations containing plant extracts
11/20/2002	EP1147101B1 Reverse hydroxamate inhibitors of matrix metalloproteinases
11/20/2002	EP1107732B1 Oral liquid mucoadhesive compositions
11/20/2002	EP1098645B1 Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ards) and infant respiratory distress syndrome (irds)
11/20/2002	EP1047688B1 Thiophene nitrone compounds
11/20/2002	EP1042301B1 Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
11/20/2002	EP1042285A4 iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
11/20/2002	EP1002542B1 Use of vip for the preparation of a medicament for treating the endotoxic shock in mammals
11/20/2002	EP0984952B1 A new salt
11/20/2002	EP0946189B1 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
11/20/2002	EP0929530B1 Quinazoline derivatives and pharmaceutical compositions containing them
11/20/2002	EP0920422B1 Crytalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
11/20/2002	EP0912568B1 imidazopyridines
11/20/2002	EP0833828B1 Rapamycin derivatives
11/20/2002	EP0831851B1 Use of pseudopterosins for promoting wound healing

1 ... 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 ... 1564